Analyst on Ambu downgrade: Doesn't change investment case

Sydbank analyst calls the adjustment "discouraging news" for the medtech company, but highlights that the visualization business isn't affected.

BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

Published: 06.10.21 at 12:15

Tuesday evening's Ambu downgrade is obviously not good news, having made waves in the share price on Wednesday, but the medtech company's announcement really doesn't change its investment case, at least according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

"On the face of things it seems to be discouraging news from Ambu. Having said that, Ambu is priced on the expectations for its visualization business, and this isn't where the company has been affected by shipment delays," Løntoft Hansen says, highlighting, however, that the challenges in shipping, which cost the company DKK 75m (USD 11.7m) in the fourth quarter, will bleed into the next financial year.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.